StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$4.48−0.22 (-4.68%)

Close on Nov 18, 2026Market cap $277.06MP/E –Yield –

Kyverna Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for Kyverna Therapeutics

Kyverna Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Kyverna Therapeutics figures

See a number that looks wrong?